SCHEMBL275677

SCHEMBL275677

C=C(N=Cc1cc(F)ccc1Oc1ccc(F)cc1)O[Si](C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
HTT P42858 2/20 0.35
HPGD P15428 2/20 0.35
SCN9A Q15858 5/20 0.34
SCN4A P35499 2/20 0.33
PTGER4 P35408 1/20 0.32
PTGER2 P43116 1/20 0.32
SLC6A4 P31645 3/20 0.32
HTR2A P28223 2/20 0.32
KCNH2 Q12809 2/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
MAP2K1 Q02750 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279179 1.00 LMNA (0.44) LMNAALDH1A1L3MBTL1CRHBPCRHR2
SCHEMBL279191 0.94 LMNA (0.43) LMNAALDH1A1L3MBTL1HTTHPGD
SCHEMBL274647 0.94 LMNA (0.43) LMNAALDH1A1L3MBTL1HTTHPGD
SCHEMBL279339 0.91 LMNA (0.40) LMNAALDH1A1L3MBTL1CRHBPCRHR2
SCHEMBL278967 0.90 TBXA2R (0.38) LMNAALDH1A1L3MBTL1SCN9ASLC6A4
SCHEMBL275612 0.90 TBXA2R (0.38) LMNAALDH1A1L3MBTL1SCN9ASLC6A4
SCHEMBL275415 0.88 MAPT (0.38) L3MBTL1HPGDSLC6A4MAPTSLC6A2
SCHEMBL279428 0.88 MAPT (0.38) L3MBTL1HPGDSLC6A4MAPTSLC6A2
SCHEMBL8043283 0.86 ERN1 (0.38) LMNAALDH1A1L3MBTL1HTTMAPT
SCHEMBL275811 0.84 PPARA (0.36) LMNAALDH1A1L3MBTL1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT LMNA 549/4885ALDH1A1 138/4885L3MBTL1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.